US 7,304,174

Application 10/830,480 · Granted Dec 4, 2007

Casr antagonist

Estimated expiration

September 24, 2025

Expired 424 days ago

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Apr 23, 2004
+ 20 years
Apr 23, 2024
PTA +519d
Sep 24, 2025
No TD
—
Final
Sep 24, 2025

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
April 23, 2004
Earliest effective filing
April 23, 2004
Issue date
December 4, 2007
PTA
+519 days
Base expiry (before PTA)
April 23, 2024

April 23, 2004 + 20 years = April 23, 2024 + 519 PTA days = September 24, 2025

Continuity chain

No continuity chain; the patent’s own filing date was used.

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 10/830,480 · US 7,304,174

PatentReply compiles the prosecution history behind US 7,304,174: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US7304174

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.